Introduction
One of the major problems in cancer chemotherapy is the development of resistance to drugs. Several mechanisms of drug resistance have been elucidated; some operate against a particular drug, while others affect a group of' structurally unrelated anticancer agents, as in multidrug resistance (MDR). Doxorubicin, vincristine and etoposide are examples of drugs subjected to the MDR mechanism. Multidrug-resistant cells express an efflux pump, P glycoprotein (Pgp), which expels anticancer drugs from the cells. Expression of the multidrug transporter can be demonstrated by anti-Pgp monoclonal antibodies, or at the DNA and RNA level by blotting techniques [26] . Resistance to a specific drug may be caused by several mechanisms. For instance, resistance to cisplatin is related to reduced drug accumulation, increased detoxification and increased DNA repair [2] . The development of resistance to anti-cancer drugs urges the search for alternative treatment modalities, for example immunotherapy. Adoptive immunotherapy using interleukin-2 (IL-2) and cytotoxic cells [lymphokineactivated killer (LAK) cells] has proven to be effective in renal cell cancer. Response rates up to 35% have been reported. In melanoma, responses up to 21% were found. Response rates in colon carcinoma were lower (13%) [32] . All these rumors intrinsically express the MDR phenotype at a high frequency [15] (W. Van de Vrie et al., in preparation).
Before immunotherapy can be used as an alternative treatment after failure of chemotherapy, it is important to know whether there might be a correlation between drug resistance and sensitivity or resistance to immunotherapy. Reports in the literature have yielded conflicting data about a possible correlation between drug resistance, especially MDR, and resistance to natural killer (NK) and LAK cell lysis [33, 34] . We investigated this subject in four cell lines of a rat colon carcinoma with different mechanisms and levels of drug resistance. In our model drug resistance was not associated with changes in sensitivity to NK-cell-mediated lysis. Only minor alterations in sensitivity to IL-2/adherent LAK (aLAK) cell lysis were observed.
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Materials and methods
Animals. Male rats of the inbred WAG/RIJ (RT1 u) strain were obtained from Harlan-CPB (Austerlitz, The Netherlands). Animals were bred under specific-pathogen-free conditions and fed standard rat chow (Hope Farms, Woerden, The Netherlands) and water ad libitum. In the experiments, rats of 12-18 weeks old, weighing 220-280 g, were used.
Ceil lines. CC531 is a rat colon adenocarcinoma, which was induced chemically in the WAG rat with 1,2-dimethylhydrazine. The moderately differentiated tumor is weakly immunogenic, as determined by the method described by Prehn and Main [27] , and transplantable in syngeneic rats [20] . Following subcutaneous implantation and subsequent resection, the tumor metastasizes to the lungs. In vivo the tumor is resistant to most anticancer drugs and only at the maximal tolerable dose were significant growth-retarding effects observed [ 19] (unpublished observations). Cisplatin was reported to be one of the most effective drugs against CC531 [19] . Moderate sensitivity to immunotherapeutic agents like interferon "/and tumor necrosis factor c~ in vitro and in vivo has been shown in previous studies [8, 20, 21, 36] . In vitro CC531, the parental cell line (CC531-PAR), grows as a monolayer in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% heat-inactivated fetal calf serum (FCS), L-aspargine (50 mg/1), glutamic acid (2 mM), 100 IU/ml penicillin and 100 gg/ml streptomycin, all obtained from Gibco (Paisley, UK), in a humidified atmosphere of 5% CO~J95% air at 37~ CC531-PAR intrinsically expresses the MDR phenotype. We recently reported on the reversibility of MDR in vitro and in vivo in this model [38] . In vitro drug resistant sublines were induced by continuous incubation with colchicin (CC531-COL) and cisplatin (CC531-CIS). Established cell lines were maintained in the presence of 0.2 gM colchicin and 0.75 gM cisplatin (cis-diaminedichloroplatinum) respectively [14] .
Compared to the parental line, CC531-COL shows enhanced resistance to drugs of the MDR phenotype (colchicin 33 x, daunorubicin 10 x ) and to cisplatin (5.5 x ). CC531-CIS is resistant to cisplatin (9.8 • ), while it has approximately the same sensitivity to other drugs as the parental line. From CC531-COL a revertant line (CC531-REV) was isolated that is more sensitive to drugs of the MDR phenotype than the parental line a RF, resistance factor. Drug sensitivity was determined with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric cell-growth-inhibition assay for different drugs. In the table the relative sensitivity of the cell lines compared to the parental line is given. The sensitivity of CC531-PAR is arbitrarily defined as 1 b DNR, daunorubicin; COL, colchicin; VBL, vinblastine; CIS, cis-diaminedichloroplatinum; VPL, verapamil c SR, sensitization ratio. The DNR concentration that causes 50% growth inhibition (ICs0) in the MTT assay divided by the DNR concentration in the presence of 6.6 pM verapamil that reaches the ICs0 a The percentage intracelhilar fluorescent DNR determined in an accumulation assay by flow cytometry. The fluorescence of DNR in the parental line is defined as 100% e ND, not done f P glycoprotein expression in cells was determined by flow cytometry with the monoclonal antibody C-219. The immunofluorescence staining is indicated with +++ for bright staining, ++ for clear, + for moderate, + for feeble, and -for no staining (resistance to colchicin 0.6 x, to daunorubicin 0.25 x ), but the resistance to cisplatin is maintained (4 x ) as in the CC531-COL line [13, 14] . See Table 1 for characteristics. YAC-1, a mouse T cell lymphoma, sensitive to NK cell lysis, was used as a positive control in the NK cell experiments. P815, a mouse mastocytoma, NK-cell-lysis-resistant but sensitive to LAK cell lysis, was used as a negative control in NK cell experiments and as a positive control in aLAK cell cytotoxicity tests. Both cell lines were grown in suspension in RPMI-1640 medium, (Dutch modification; Gibco) supplemented with 10% FCS, 2 mM glutamine, 100 IU/ml penicillin and 100 gg/ml streptomycin.
Cell lines were grown in drug-free medium for at least 72 h before being used in tests. Adherent growing cells were isolated by trypsinization. Viability, determined by trypan blue exclusion, was more than 90% in all experiments (85% for YAC-1 and P815 cells). Regular screening for Mycoplasma infection was performed.
The NK and aLAK cell experiments were conducted in complete RPMI medium (10% FCS) without HEPES buffer. Complete LAK medium for the generation of aLAK cells consisted of complete RPMI medium plus 1000 EuroCetus units IL-2/ml and 50 glVI 2-mercaptoethanol.
Chemicals. 2-Mercaptoethanol was obta!ned from J.T. Baker, Deventer, The Netherlands; interleukin-2 (IL-2) from EuroCetus, Amsterdam, The Netherlands; 1% sodium dodecyl sulfate from Merck, Darmstadt, Germany; sodium [51Cr]chromate from Amersham, Aylesbury, UK.
Preparation ofeffector cells. Spleens were removed aseptically from the rats and crushed with the hub of a syringe in complete medium. Spleen cells were incubated for 5 rain at 37~ in a buffered ammonium chloride solution to lyse the erythrocytes. For the NK cytotoxicity tests ceils were rested for 1 h in complete medium at 37~ in 25-cm 2 culture flasks (Costar, Cambridge, Mass.) to remove the macrophages by adherence to the plastic. The remaining free-floating cells were aspirated, counted, and added to 96-well round-bottomed microtiter plates (Costar). In the NK cell lysis tests effector:target (E:T) cell ratios were 200:1,100:1, 50:1 and 25:1.
For the aLAK cell cytotoxicity tests cells were passed over nylonwool columns to remove monocytes/macrophages and B cells [17] . Samples containing 2 x 108 spleen cells were added to a syringe containing 0.6 g sterile nylon wool (Cellular Products, Buffalo, N.Y.) and incubated for 1 h at 37~ The nonadherent cells were carefully washed out with 50 ml medium. These cells were cultured at a concentration of 2 x 106 cells in 75-cm 2 culture flasks in LAK medium for 24 h. Then only the cells adherent to the plastic of the flasks were cultured further in conditioned medium to make the aLAK cell bulk culture. Conditioned medium was prepared by decanting the medium from the flasks, removing the uonadherent ceils by centrifugation and passing the supernatant through a 0.45-gm Millipore filter [40] . After 72 h all cultured cells were collected; the adherent cells by adding EDTA and scraping the flask with a rubber policeman. In the aLAK cell lysis experiments E:T cell ratios were 50:1, 25:1, 12.5:1 and 6.25:1.
Cytotoxicity assay. Sensitivity to NK and aLAK cells was tested in the 51Cr-release cytotoxicity assay. Samples containing 1 • 10 6 target cells were incubated for 1 h with 200 gCi 51Cr in 200 gl medium. Cells were washed three times with complete medium and counted, and 1 • 104 cells in 100 gl complete medium were added to the effector ceils (100 gl) in the plates. Spontaneous release was tested in wells containing target cells and medium (100 gl) only; maximal release was obtained by adding 100 gl 1% sodium dodecyl sulfate to target cells. Tests were performed in triplicate and all tests were repeated at least twice. Plates were incubated for 4 h at 37~ The supernatant was harvested using the Skatron supernatant collection system (Skatron, Lier, Norway). The release of 51Cr was determined by counting radioactivity in a gamma counter (LBK Wallace Ultragamma II 1280, Wallace Instruments, Stockholm, Sweden). The percentage specific cytotoxicity was calculated by the following formula: Lytic units (LU) were calculated according to the method described by Pross et al. [28] . The calculations of lytic units and of statistical significance were done on the compilations of different tests. In figures, representative experiments are shown.
Statistics. Statistical significance of the results was determined at the highest E:T ratios: 200:1 for NK cell lysis and 50:1 for aLAK cell lysis. The Student t-test (paired t-test) was used and a P value of less than 0.05 was considered significant.
Results
NK cells of the WAG rat were highly effective against the NK-sensitive YAC-1 cell line; up to 60% lysis was observed. The NK-resistant cell line P815 was not lysed at all: less than 5% lysis was recorded at the 100:1 and 200:1 E:T cell ratios. The CC531 cell lines were rather resistant to NK cell lysis. At the highest (200:1) E:T cell ratio 15%-22% specific lysis was found. See Fig. 1 . There were no significant differences in sensitivity between the CC531 cell lines.
We used aLAK cells instead of LAK cells because the adherent cells were proven to be the most effective cytotoxic cells in bulk cultures with IL-2 [40] . A representative Fig. 2 . Maximal lysis of P815 was more than 60%, while lysis of the CC531 cell lines did not exceed 20%. At the maximal E:T ratio of 50:1 only minor differences in lysis were observed between some cell lines. CC531-CIS was significantly more sensitive to aLAK lysis compared to the least lysable cell line CC531-COL.
As there were indications that the resistance to lysis by cytotoxic cells could be overcome by prolonging the incubation period, we extended the aLAK tests to 20 h. In these prolonged tests P815 cells appeared to be fragile as the spontaneous release was more than 25%. Specific lysis of P815 by aLAK cells was not enhanced by longer exposure to the cytotoxic cells in comparison with 4 h exposure. In all CC531 cell lines spontaneous release after 20 h was about 20%; CC531-PAR: 19.7 + 2.6% (SD), CC531-COL: 19.8 + 3.7%, CC531-REV: 20.1 ___ 7.3%, and CC531-CIS: 20.6 + 6.0%. In this prolonged assay none of the CC531 cell lines proved resistant to lysis by aLAK cells; specific lysis was more than 25% in all cell lines. Differences in sensitivity between the sublines became clearer (Fig. 3) . In the compilation of tests CC531-COL appeared the most resistant line and, at the 50:1 E:T ratio, less than 30% lysis was found. CC531-REV and CC531-CIS proved to be the most lysable with more than 50% lysis after 20 h. The differences between CC531-REV and CC531-COL, and CC531-CIS and CC531-COL were significant. The same significant difference was found for CC531-REV compared to CC531-PAR, while CC531-CIS was found significantly more sensitive to aLAK lysis than the parental line in three out of four tests, but not in the compilation of four tests. Lyric units as values of cytotoxicity show the same order of sensitivity to aLAK cell mediated lysis in the 20-h assay, but differences between the cell lines are small. See Table 2 .
Discussion
CC531 cells appeared to be rather resistant to tysis by cytotoxic cells. NK cell lysis was below 22% in all cell lines even at an E:T ratio of 200:1. No differences in specific lysis were observed between the CC531 cell lines. Lysis by IL-2-induced cytotoxic cells, aLAK cells, still was very low at a 50:1 E:T ratio, but some difference between the cell lines became apparent. We studied these differences in a prolonged assay. None of the cell lines was found to be completely resistant to aLAK lysis. The most drug-sensitive cell line, CC531-REV, with the least expression of Pgp was the most sensitive to aLAK lysis, while the most drug resistant cell line, CC531-COL, seemed the most resistant to aLAK lysis.
So far conflicting results have been reported about a possible correlation between drug resistance and sensitivity to NK cell lysis. Various reports about doxorubicin-induced drug resistance showed enhanced resistance to NKcell-mediated lysis in doxorubicin-resistant sublines [3, 6, 41, 43] . In MDR cell lines, both no change in sensitivity [1, 5, 16, 35] and also enhanced sensitivity to NK cell lysis compared to the parental cell lines [34] has been described. In contrast, Woods et al. reported diminished NK sensitivity of an MDR subline with enhancement of sensitivity in a revertant cell line [42] . Treichel et al. only found this relationship for MDR cell lines that express Pgp, and not for non-Pgp MDR cell lines [37] .
With regard to LAK cell sensitivity, various studies show no difference in lysability between drug-resistant cell lines and their parental lines [1, 3, 4, 12, 16, 25, 35] . Enhanced sensitivity as well as enhanced resistance of MDR cell lines to LAK cell lysis has been reported by others [10, 11, 12, 18, 30, 37 ]. An inverse relationship has also been found: the induction of LAK resistance in melanoma cell lines rendered these more sensitive to doxorubicin [29] . Kimmig et al. found that LAK resistance correlated with the level of Pgp expression. A revertant cell line that was as drug sensitive as the parental line was found to be as lysable by LAK cells as the parental ceil line [18] . We did a comparable observation with the CC531 cell lines in the prolonged aLAK lysis assay.
Explanations for the phenomenon of differences in sensitivity to cytotoxic cells between drug-sensitive and drugresistant cells have been sought in differences in the expression of cell membrane molecules. In most studies no correlation between MDR expression, NK or LAK cell resistance and expression of MHC class I and II antigens was observed [10, 31, 35] . With regard to adhesion molecules a correlation between enhanced LAK cell lysis and ICAM-1 and LFA-3 expression in MDR cell lines was described [31] , but other authors could not confirm these results using other cell lines [35] .
To our knowledge only few reports about the association between cisplatin resistance and NK/LAK cell resistance have been published. In most experiments no influence of cisplatin resistance on sensitivity to LAK-cell-mediated lysis was observed [4, 16, 25, 29] . In one of their cisplatin-resistant cell lines Ohtsu et al. found enhanced sensitivity to LAK cell lysis [25] . Allevana et al. reported significant lysis by LAK cells of freshly isolated tumor cells from ovarian cancer patients that were refractory to chemotherapy with cisplatin [4] . In a recent article shortterm pretreatment of cancer cells with cisplatin was reported to render these cells more sensitive to cytotoxic cells [24] . We observed enhanced lysis by aLAK cells of the cisplatin-resistant cell line CC531-CIS. In CC531-COL and CC531-REV cells a moderate resistance to cisplatin was found, about half the resistance of CC531-CIS. In 341 these two cell lines an association between their MDR phenotype and LAK resistance can be supposed, while the resistance to cisplatin seems of no importance. It is very possible that the colchicin induced MDR cell line CC531-COL and its revertant CC531-REV have a different mechanism of cisplatin resistance from CC531-CIS, as this resistance was induced differently.
It is clear from our results and those of others that basic research has not yet provided coherent data on the relationship between drug resistance and sensitivity to immunotherapy. The lack of coherence in the results may be inherent to the different cell lines and the diversity of methods used to induce resistance. Possibly this reflects the heterogeneity of sensitivity and resistance to drugs and immunotherapy in the clinical situation. Our results seem to indicate that drug resistance does not preclude the use of immunotherapy with IL-2 and LAK cells, but enhancement of the efficacy of immunotherapy is necessary. With regard to Pgp-expressing multidrug-resistant tumors, an attractive approach might be to turn the strength of MDR cells into their weakness. This can be done by using antibodies against the multidrug transporter Pgp. Immunotoxin therapy using the anti-Pgp antibody MRK16 coupled to Pseudomonas exotoxin has been shown to be effective against MDR cells in vitro and in vivo [9, 22, 23] . Another possible method of targeted immunotherapy is the use of bispecific monoclonal antibodies directed against Pgp on one hand and against an antigen on cytotoxic cells on the other [7, 39] . Further research in this direction is warranted.
